DDW_Charles River_Logo_2_web

Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to support biochemical/biophysical characterisation of biotherapeutic molecules including antibodies.

In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet® Bio-Layer Interferometry (BLI) into its monoclonal antibody discovery workflow for discovery campaigns, antibody optimisation, and IgG characterisation. The webinar elaborates on the use of the Octet® BLI for quality control of proteins, high throughput hit screening with crude single chain library clones and kinetic determination of antibody-antigen binding.

Key Learning Objectives from this webinar:

  • Use of the Octet® BLI platform for ultrahigh throughput hit screening and for off-rate ranking of crude periplasmic extract samples during early antibody discovery.

  • Octet® BLI applications in reagent quality control including binding interaction studies.

Watch the Webinar